Literature DB >> 25981488

Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis.

Mark H Rozenbaum1, Marie-Josee J Mangen2, Susanne M Huijts3, Tjip S van der Werf4, Maarten J Postma5.   

Abstract

BACKGROUND: Community-acquired pneumonia (CAP) is one of the most common acute infections associated with a substantial clinical and economic burden. There have been few studies assessing incidence rate, duration of hospitalization, and costs of hospitalized CAP by age and care-setting.
METHODS: A retrospective study was conducted using a nationwide Dutch database containing healthcare claims data of 16.7 million inhabitants. Patients with at least one claim with a discharge diagnosis of CAP between January 2008 and December 2011 were selected. The main outcome measures considered were the incidence rate, duration of hospitalization, and the direct costs of hospitalized CAP stratified by age and care-setting.
RESULTS: In total, 195,372 CAP cases were included in the analysis resulting in an average incidence of 295 per 100,000 population per year. Sixty-three percent (123,357) of the included patients were hospitalized for 1 or more nights, of which 5.9% (n=7241) spent at least one night in the Intensive Care Unit (ICU). Overall, these 123,357 patients spent 824,985 days in the hospital of which 48,324 were spent on the ICU. The mean duration of hospitalization of ICU patients and general ward patients was 15.2 days and 6.2 days, respectively. The total costs related to all 195,372 CAP episodes during these 4 years were €711 million, with the majority (76%) occurring among those aged 50 years and older. Median (and mean) costs were dependent on age and type of care with costs ranging from €344 (€482) per episode for 0-9 year olds treated in the outpatient hospital setting up to €10,284 (€16,374) per episode for 50-64 year olds admitted to the ICU.
CONCLUSION: There is a large variation in terms of incidence, disease burden and costs across different age groups and the treatment setting. Effective interventions, targeted at older adults, to prevent pneumonia could reduce the (financial) burden due to pneumonia.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Community acquired pneumonia; Costs; Database; Duration of hospitalization; Incidence; Length of stay; Pneumonia

Mesh:

Year:  2015        PMID: 25981488     DOI: 10.1016/j.vaccine.2015.05.001

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

Review 1.  The Use of Statins and Risk of Community-Acquired Pneumonia.

Authors:  Mohammed A Batais; Abdur Rahman Khan; Aref A Bin Abdulhak
Journal:  Curr Infect Dis Rep       Date:  2017-08       Impact factor: 3.725

2.  Incidence and disease burden of community-acquired pneumonia in southeastern China: data from integrated medical resources.

Authors:  Ning Jiang; Ran Li; Jing Bao; Yu Xie; Xiqian Ma; Yukun He; Yan Yu; Yusheng Chen; Hongru Li; Yali Zheng; Qing Xue; Jiangxi Wu; Yu Xu; Chuanxi Fu; Zhancheng Gao
Journal:  Hum Vaccin Immunother       Date:  2021-11-19       Impact factor: 3.452

3.  Population-based estimates of the burden of pneumonia hospitalizations in Hong Kong, 2011-2015.

Authors:  Xue Li; Joseph E Blais; Ian C K Wong; Anthony W Y Tam; Benjamin J Cowling; Ivan F N Hung; Esther W Y Chan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-01-25       Impact factor: 3.267

Review 4.  Chlamydia psittaci (psittacosis) as a cause of community-acquired pneumonia: a systematic review and meta-analysis.

Authors:  L Hogerwerf; B DE Gier; B Baan; W VAN DER Hoek
Journal:  Epidemiol Infect       Date:  2017-09-26       Impact factor: 4.434

5.  Hospitalization costs for community-acquired pneumonia in Dutch elderly: an observational study.

Authors:  Conrad E Vissink; Susanne M Huijts; G Ardine de Wit; Marc J M Bonten; Marie-Josée J Mangen
Journal:  BMC Infect Dis       Date:  2016-09-02       Impact factor: 3.090

6.  The economic burden of childhood pneumococcal diseases in The Gambia.

Authors:  Effua Usuf; Grant Mackenzie; Sana Sambou; Deborah Atherly; Chutima Suraratdecha
Journal:  Cost Eff Resour Alloc       Date:  2016-02-17

Review 7.  Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns.

Authors:  Catia Cilloniz; Ignacio Martin-Loeches; Carolina Garcia-Vidal; Alicia San Jose; Antoni Torres
Journal:  Int J Mol Sci       Date:  2016-12-16       Impact factor: 5.923

8.  Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.

Authors:  Cornelis H van Werkhoven; Douwe F Postma; Marie-Josee J Mangen; Jan Jelrik Oosterheert; Marc J M Bonten
Journal:  BMC Infect Dis       Date:  2017-01-10       Impact factor: 3.090

9.  Economic burden of community-acquired pneumonia among elderly patients: a Japanese perspective.

Authors:  Keiko Konomura; Hideaki Nagai; Manabu Akazawa
Journal:  Pneumonia (Nathan)       Date:  2017-12-05

10.  Pneumonia treatment by photodynamic therapy with extracorporeal illumination - an experimental model.

Authors:  Mariana C Geralde; Ilaiáli S Leite; Natalia M Inada; Ana Carolina G Salina; Alexandra I Medeiros; Wolfgang M Kuebler; Cristina Kurachi; Vanderlei S Bagnato
Journal:  Physiol Rep       Date:  2017-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.